Article
Nanoscience & Nanotechnology
Jiaojiao Chen, Yarong Song, Wenqian Yang, Jianhui Guo, Saihui Zhang, Dong Wan, Yonghui Liu, Jie Pan
Summary: In this study, tumor-targeted polymeric micelles were synthesized, and drug release was achieved through extracellular enzyme response and intracellular reduction response, thereby improving the disadvantages of chemotherapy drugs. The experiments demonstrated that this method had good anti-tumor activity in vivo and reduced toxic side effects on normal tissues.
ACS APPLIED NANO MATERIALS
(2023)
Article
Chemistry, Physical
Yupeng Guan, Chengyuan Xing, Tongyu Tong, Xinyi Zhang, Jun Li, Huikun Chen, Junfeng Zhu, Yang Kang, Jun Pang
Summary: Conventional chemotherapy is limited by poor water solubility, inferior tissue targeting, and systemic toxic effects. In this study, smart dual responsive nanocarriers that release chemotherapy drugs in response to high levels of reactive oxygen species (ROS) and esterase in the tumor microenvironment have been developed. These nanocarriers have the ability to amplify ROS and sustain the release of chemotherapeutics, leading to enhanced sensitivity to chemotherapy. They show promise for the treatment of prostate cancer and synergistic cancer therapy.
JOURNAL OF COLLOID AND INTERFACE SCIENCE
(2022)
Article
Pharmacology & Pharmacy
Giorgiana Negrea, Valentin-Florian Rauca, Marta Szilvia Meszaros, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Dana Muntean, Alina Sesarman, Manuela Banciu
Summary: This study proposes a novel combination therapy that selectively targets both tumor-associated macrophages and melanoma cells, leading to strong inhibition of tumor growth and modulation of the tumor-immune microenvironment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sona Gandhi, Indrajit Roy
Summary: Non-small-cell lung cancer (NSCLC) affects 2 million people worldwide and is caused by both genetic and environmental factors. Current therapeutic techniques have low efficacy, leading to a poor survival rate. Inhalable nanotherapeutic agents have the potential to improve drug delivery and minimize side effects. Lipid-based nanoparticles are ideal for inhalable delivery due to their high drug loading, sustained release, and biocompatibility. Various lipid-based nanoformulations have been developed for inhalable delivery in NSCLC models. This review discusses the current developments and future prospects of these nanoformulations in NSCLC treatment.
Article
Chemistry, Multidisciplinary
Weizhi Chen, Yang Yuan, Cheng Li, Hui Mao, Baorui Liu, Xiqun Jiang
Summary: This study reveals that blocking cancer cell signaling can disrupt tumor extracellular matrix, and it is demonstrated that multireceptor-mediated modulation of tumor ECM can reverse tumor microenvironment remodeling. These findings are not only important for understanding the regulatory role of cancer cells in tumor microenvironment development, but also introduce a new therapeutic platform or strategy for cancer treatment.
ADVANCED MATERIALS
(2022)
Article
Biochemistry & Molecular Biology
Hui Wen Yong, Marine Ferron, Melanie Mecteau, Teodora Mihalache-Avram, Sylvie Levesque, Eïric Rheaume, Jean-Claude Tardif, Ashok Kakkar
Summary: In this study, we developed nanocarriers that could respond to dissolved CO2, varied pH, reactive oxygen species (ROS), and ROS + CO2 by utilizing a versatile tertiary amine. The results demonstrated the potential of these nanocarriers in drug release and anti-inflammatory properties.
Review
Chemistry, Multidisciplinary
Seongkyeong Yoo, Sanga Choi, Iljin Kim, In-San Kim
Summary: Extracellular vesicles (EVs) play a crucial role in cancer progression and are regulated by hypoxia. Hypoxic EVs contain specific molecules capable of reprogramming recipient cells. Using EVs as drug delivery vehicles shows promise in cancer treatment, but challenges need to be overcome.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Chemistry, Multidisciplinary
Xiaoqian Xin, Zhongxia Zhang, Xican Zhang, Jian Chen, Xi Lin, Pinghua Sun, Xiaowen Liu
Summary: Bioresponsive nanomedicine is a promising platform for efficient delivery of therapeutics to disease sites. Dynamic covalent bonds (DCBs) play a key role in the fabrication of bioresponsive nanomedicines, enabling site-specific release and targeted drug delivery for optimal therapy in various diseases.
Article
Biophysics
Sylwia Michlewska, Zuzana Garaiova, Veronika Subjakova, Marcin Holota, Ma lgorzata Kubczak, Marika Grodzicka, Elzbieta Okla, Nikolaos Naziris, Lucja Balcerzak, Paula Ortega, Francisco Javier de la Mata, Tibor Hianik, Iveta Waczulikova, Maria Bryszewska, Maksim Ionov
Summary: In this study, we combined dendritic and liposomal carriers and analyzed the biochemical and biophysical properties of these formulations. Lipid-coated dendritic carriers showed significantly improved transfection profiles and lower toxicity to erythrocyte membranes compared to noncomplexed components. The nanometric size, low polydispersity index, and reduced positive zeta potential of these complexes make them attractive for future drug delivery applications.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2023)
Article
Chemistry, Physical
Mengyi Li, Shuai Jiang, Adelina Haller, Sebastian Wirsching, Michael Fichter, Johanna Simon, Manfred Wagner, Volker Mailander, Stephan Gehring, Daniel Crespy, Katharina Landfester
Summary: This study developed a DXM-phosphate-based polyprodrug encapsulated in silica nanocontainers, showing enhanced control of inflammatory responses in liver cells, highlighting the advantage of combining the polyprodrug strategy with nanocarrier-mediated delivery for water-soluble low molecular weight drugs.
NANOSCALE HORIZONS
(2021)
Article
Polymer Science
Arjaree Jobdeedamrong, Man Theerasilp, Nutthanit Thumrongsiri, Paweena Dana, Nattika Saengkrit, Daniel Crespy
Summary: In this study, GSH-responsive and self-immolative polyprodrug nanoparticles were prepared for cancer treatment. These nanoparticles showed high drug loading and efficient redox-responsive release, displaying high cytotoxicity against cancer cells and low cytotoxicity against cancer cells treated with GSH scavenger or normal cells.
Review
Chemistry, Multidisciplinary
Srushti Mahajan, Mayur Aalhate, Santosh Kumar Guru, Pankaj Kumar Singh
Summary: Lymphomas are hematological malignancies that originate in lymph tissues and tend to spread to other organs. Traditional strategies like surgery and local treatment are not suitable for managing these tumors, but novel targeted therapies and antibody-mediated treatments have been revolutionary in their management. Nanomedicine provides targeted delivery of therapeutic agents, reducing drug resistance and toxicities, and also offers personalized medicine for different types of lymphomas.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Cell Biology
Lingkai Yang, Xin Huang, Haoyu Guo, Lutong Wang, Wenbo Yang, Wei Wu, Doudou Jing, Zengwu Shao
Summary: Osteosarcoma is the most common bone tumor affecting adolescents and children, with studies indicating that exosomes play a potential role in the progression and development of osteosarcoma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Kandasamy Vinothini, Sathish Sundar Dhilip Kumar, Heidi Abrahamse, Mariappan Rajan
Summary: Nanoparticle-based drug delivery improves drug bioavailability and stability, facilitates targeted drug delivery, and avoids premature drug release. The targeted folate-conjugated oxidized mesoporous carbon nanospheres were successfully developed for breast cancer therapy.
Review
Pharmacology & Pharmacy
Soheil Haddadzadegan, Farid Dorkoosh, Andreas Bernkop-Schnuerch
Summary: The oral administration of therapeutic peptides and proteins faces various barriers, which can be overcome by using lipid-based nanocarriers. These nanocarriers enhance the lipophilic character of the drugs and protect them from enzymatic degradation. They can penetrate mucus and absorption membranes, enabling systemic delivery of the therapeutic molecules. Lipid-based nanocarriers show promising stability and delivery efficacy.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Editorial Material
Oncology
Edna Cukierman
Summary: The study demonstrates the protu-morigenic role of pancreatic stellate cell-derived cancer-associated fibroblasts in pancreatic cancer.
Article
Multidisciplinary Sciences
Claudia Capparelli, Timothy J. Purwin, McKenna Glasheen, Signe Caksa, Manoela Tiago, Nicole Wilski, Danielle Pomante, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Janusz Franco-Barraza, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Vito W. Rebecca, Adam E. Snook, Kim Hookim, Xiaowei Xu, Edna Cukierman, Meenhard Herlyn, Andrew E. Aplin
Summary: Cellular plasticity plays a crucial role in tumor heterogeneity and phenotype switching. SOX10 is involved in the phenotypic switching of cutaneous melanoma, and cIAP1/2 inhibitors can selectively induce cell death in SOX10-deficient cells.
NATURE COMMUNICATIONS
(2022)
Article
Biology
Deborah Fanfone, Zhichong Wu, Jade Mammi, Kevin Berthenet, David Neves, Kathrin Weber, Andrea Halaburkova, Francois Virard, Felix Bunel, Catherine Jamard, Hector Hernandez-Vargas, Stephen W. G. Tait, Ana Hennino, Gabriel Ichim, Edna Cukierman
Summary: Breast cancer cells develop resistance to cell death triggered by loss of adhesion during metastasis, which is mediated by Inhibitory of Apoptosis Proteins. Mechanically stressed cancer cells with resistance to cell death display enhanced cell motility and evasion from immune surveillance, and have increased metastatic potential.
Article
Oncology
Tiffany Luong, Edna Cukierman
Summary: Pancreatic cancer patients have low survival rates, and a drug has been found to potentially normalize the function of cancer-associated fibroblasts.
Article
Oncology
Noreen McBrearty, Christina Cho, Jinyun Chen, Farima Zahedi, Amy R. Peck, Enrico Radaelli, Charles-Antoine Assenmacher, Clarice Pavlak, Anne Devine, Pengfei Yu, Zhen Lu, Hongru Zhang, Jinyang Li, Jason R. Pitarresi, Igor Astsaturov, Edna Cukierman, Anil K. Rustgi, Ben Z. Stanger, Hallgeir Rui, Serge Y. Fuchs
Summary: Cholesterol dependence is a key characteristic of pancreatic ductal adenocarcinoma (PDAC). Loss of CH25H in PDAC cells leads to cholesterol accumulation, promoting tumor progression and interfering with immunotherapies. Restoration of CH25H expression inhibits PDAC cell proliferation, slows tumor growth, and enhances immune response under cholesterol deficit conditions.
MOLECULAR CANCER RESEARCH
(2023)
Article
Biology
Takuya Kato, Robert P. Jenkins, Stefanie Derzsi, Melda Tozluoglu, Antonio Rullan, Steven Hooper, Raphael A. G. Chaleil, Holly Joyce, Xiao Fu, Selvam Thavaraj, Paul A. Bates, Erik Sahai, Edna Cukierman
Summary: Cancers, such as squamous cell carcinoma, invade as multicellular units and the mode of invasion is determined by factors including matrix proteolysis and cell-cell junctions. Wide strands of invasion are formed through matrix proteolysis and cell-cell junctions, and efficient invasion also requires cell-cell junctions in response to uniform directional cues. The ability to generate wide invasive strands is linked to effective growth in a three-dimensional environment. The most aggressive cancer behavior is achieved at high levels of both cell-cell adhesion and matrix proteolysis, contrary to expectations.
Article
Biochemistry & Molecular Biology
Frederick R. Adler, Alexander R. A. Anderson, Abhinav Bhushan, Paul Bogdan, Jose Javier Bravo-Cordero, Amy Brock, Yun Chen, Edna Cukierman, Kathleen E. DelGiorno, Gerald V. Denis, Meghan C. Ferrall-Fairbanks, Zev Jordan Gartner, Ronald N. Germain, Deborah M. Gordon, Ginger Hunter, Mohit Kumar Jolly, Loukia Georgiou Karacosta, Karthikeyan Mythreye, Parag Katira, Rajan P. Kulkarni, Matthew L. Kutys, Arthur D. Lander, Ashley M. Laughney, Herbert Levine, Emil Lou, Pedro R. Lowenstein, Kristyn S. Masters, Dana Pe'er, Shelly R. Peyton, Manu O. Platt, Jeremy E. Purvis, Gerald Quon, Jennifer K. Richer, Nicole C. Riddle, Analiz Rodriguez, Joshua C. Snyder, Gregory Lee Szeto, Claire J. Tomlin, Itai Yanai, Ioannis K. Zervantonakis, Hannah Dueck
Summary: Collective cell behavior plays a crucial role in all stages of cancer progression. Exploring how this behavior emerges through cell-cell interactions and decision-making is essential for advancing our knowledge of cancer biology and developing new therapeutic approaches. This article summarizes an interdisciplinary discussion on multicellular behavior in cancer, highlights insights from other scientific disciplines, and identifies future research directions.
Article
Multidisciplinary Sciences
Matthew Zibelman, Alexander W. MacFarlane, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S. Denlinger, Efrat Dotan, Daniel M. Geynisman, Angela Jain, Lainie Martin, Elias Obeid, Karthik Devarajan, Karen Ruth, R. Katherine Alpaugh, Essel Al-Saleem Dulaimi, Edna Cukierman, Margret Einarson, Kerry S. Campbell, Elizabeth R. Plimack
Summary: This study reports the results of a phase I dose escalation trial of nivolumab in combination with IFN-γ in patients with advanced solid tumors. The combination therapy showed good safety and achieved therapeutic effects in some patients, suggesting that the combination of immune checkpoint blockade and IFN-γ may be an effective treatment strategy for cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Kristopher S. Raghavan, Ralph Francescone, Janusz Franco-Barraza, Jaye C. Gardiner, Debora B. Vendramini-Costa, Tiffany Luong, Narges Pourmandi, Anthony Andren, Alison Kurimchak, Charline Ogier, Paul M. Campbell, James S. Duncan, Costas A. Lyssiotis, Lucia R. Languino, Edna Cukierman
Summary: It is projected that pancreatic cancer will become the second deadliest cancer in the United States in 5 years. Pancreatic ductal adenocarcinoma (PDAC) is characterized by a unique tumor microenvironment rich in cancer-associated fibroblasts (CAFs) and a dense extracellular matrix (ECM). These pathogenic CAF/ECM units lead to the collapse of local blood vessels, resulting in a nutrient-poor tumor microenvironment. PDAC cells are able to survive nutrient stress through support from CAF-secreted small extracellular vesicles (sEVs). The expression of NetrinG1 (NetG1) in CAFs and active Integrin ct5131 in multivesicular bodies are associated with poor patient survival. NetG1+ CAFs secrete sEVs that promote Akt-mediated survival in nutrient-deprived PDAC cells and protect them from apoptosis.
CANCER RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
Caitlin E. Jones, Joe T. Sharick, Steven T. Sizemore, Edna Cukierman, Anne Marie Strohecker, Jennifer L. Leight
Summary: Extracellular matrix alignment is important for cancer metastasis and patient outcomes, but the mechanisms controlling matrix organization are not well understood. This study developed a high-throughput screening platform to identify proteins that regulate matrix alignment. Screening a kinase inhibitor library led to the discovery of potential regulators.
CANCER RESEARCH COMMUNICATIONS
(2022)
Meeting Abstract
Oncology
Debora B. Vendramini-Costa, Ralph Francescone, Janusz Franco-Barraza, Tiffany Luong, Esteban Martinez, Stephen Sykes, Nina G. Steele, Benjamin L. Allen, Marina Pasca di Magliano, Dmitry I. Zhigarev, Charline Ogier, Igor Astsaturov, Kathy Q. Cai, Andres J. Klein-Szanto, Huamin Wang, Kerry Campbell, Edna Cukierman
Meeting Abstract
Oncology
Alexander Metz, Marya Kozinova, Robert Uzzo, Jessica Peskin, Michael Slifker, Janusz Franco-Barraza, Edna Cukierman, Philip Abbosh
Meeting Abstract
Oncology
Charline Ogier, Alena Klochkova, Battuya Bayarmagnai, Linara Gabitova, Diana Restifo, Aizhan Surumbayeva, Janusz Franco-Barraza, Debora Vendramini Costa, Ralph Francescone, Jaye Gardiner, Emmanuelle Nicolas, Elizabeth A. Handorf, Kathy Q. Cai, Edna Cukierman, Igor Astsaturov
Meeting Abstract
Oncology
Charline Ogier, Alena Klochkova, Linara Gabitova-Cornell, Battuya Bayarmagnai, Diana Restifo, Aizhan Surumbayeva, Debora Barbosa Vendramini-Costa, Ralph Francescone, Janusz Franco-Barraza, Jaye Gardiner, Emmanuelle Nicolas, Andrei Efimov, Elizabeth A. Handorf, Kathy Q. Cai, Bojana Gligorijevic, Edna Cukierman, Igor Astsaturov
Meeting Abstract
Oncology
Debora Barbosa Vendramini-Costa, Ralph Francescone, Tiffany Luong, Janusz Franco-Barraza, Igor Astsaturov, Kathy Q. Cai, Andres J. Klein-Szanto, Huamin Wang, Kerry Campbell, Edna Cukierman
Article
Pharmacology & Pharmacy
Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci
Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas
Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li
Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.
BIOCHEMICAL PHARMACOLOGY
(2024)
Review
Pharmacology & Pharmacy
Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang
Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.
BIOCHEMICAL PHARMACOLOGY
(2024)
